These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7093395)

  • 21. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 22. Changes in psychopathology in relation to EEG variables and visual averaged evoked responses (V.AER) in schizophrenic patients treated with penfluridol or thiothixene.
    d'Elia G; Jacobsson L; von Knorring L; Mattsson B; Mjörndal T; Oreland L; Perris C; Rapp W
    Acta Psychiatr Scand; 1977 Apr; 55(4):309-18. PubMed ID: 855677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
    Tandon R; Goldman RS; Goodson J; Greden JF
    Biol Psychiatry; 1990 Jun; 27(12):1323-6. PubMed ID: 2364120
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 25. Thiothixene. Its range of therapeutic activity.
    Oliveros RT; Ban TA; Lehmann HE; Sterlin C; Saxena BM
    Int Z Klin Pharmakol Ther Toxikol; 1970 Jan; 3(1):26-9. PubMed ID: 4909376
    [No Abstract]   [Full Text] [Related]  

  • 26. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 27. Thiothixene and the thioxanthenes.
    Ban TA; Lehmann HE
    Adv Biochem Psychopharmacol; 1974; 9(0):481-6. PubMed ID: 4836220
    [No Abstract]   [Full Text] [Related]  

  • 28. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 29. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 30. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 31. Correlation of initial thiothixene serum levels and clinical response. Comparison of fluorometric, gas chromatographic, and RBC assays.
    Yesavage JA; Holman CA; Cohn R; Lombrozo L
    Arch Gen Psychiatry; 1983 Mar; 40(3):301-4. PubMed ID: 6830409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Weight gain and clozapine].
    Jalenques I; Tauveron I; Albuisson E; Audy V
    Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
    [No Abstract]   [Full Text] [Related]  

  • 33. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial.
    Guillem F; Chouinard S; Poulin J; Godbout R; Lalonde P; Melun P; Bentaleb LA; Stip E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):934-45. PubMed ID: 16580765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stroop interference effect in schizophrenic patients: an electrophysiological approach.
    Markela-Lerenc J; Schmidt-Kraepelin C; Roesch-Ely D; Mundt C; Weisbrod M; Kaiser S
    Int J Psychophysiol; 2009 Mar; 71(3):248-57. PubMed ID: 19007825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 37. Electrodermal activity and therapeutic response to neuroleptic treatment in chronic schizophrenic in-patients.
    Schneider SJ
    Psychol Med; 1982 Aug; 12(3):607-13. PubMed ID: 7134318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subjective response to antipsychotic drugs.
    Van Putten T; May PR; Marder SR; Wittmann LA
    Arch Gen Psychiatry; 1981 Feb; 38(2):187-90. PubMed ID: 7212946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
    Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
    Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.